Luke Ouma
Sarah Al-Ashmori
Samuel Sarkodie
Shaun Hiu
Dorcas Kareithi
et al. | Master protocols in Low-and-Middle income countries: A review of current use, limitations, and opportunities for precision medicine | 2024 |
|
Dr Leher Gumber
Dr Opeyemi Agbeleye
Alex Inskip
Ross Fairbairn
Madeleine Still
et al. | Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions | 2024 |
|
Dr Jingky Lozano-Kuehne
| A subset of non-small cell lung cancer patients treated with Pemetrexed show 18F-Fluorothymidine “Flare” on Positron Emission Tomography | 2023 |
|
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
| Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0) | 2023 |
|
Dr Jingky Lozano-Kuehne
| Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naïve patients with cancer: Updated safety data | 2023 |
|
Dr Jingky Lozano-Kuehne
| Spatial and temporal intra-tumoural heterogeneity in advanced High-Grade Serous Ovarian Cancer: implications for surgical and clinical outcomes | 2023 |
|
Dr Jingky Lozano-Kuehne
| [18F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed | 2022 |
|
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
Professor Ruth Plummer
| Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer | 2022 |
|
Dr Jingky Lozano-Kuehne
| The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [18F]GE-226, a first-in-patient study | 2022 |
|
Dr Jingky Lozano-Kuehne
| Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: an international, multicentre, retrospective study | 2021 |
|
Dr Jingky Lozano-Kuehne
| [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer | 2020 |
|
Dr Jingky Lozano-Kuehne
| Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy | 2020 |
|
Dr Jingky Lozano-Kuehne
| [18F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study | 2019 |
|
Dr Jingky Lozano-Kuehne
| [18F]Fluciclatide PET As A Biomarker Of Response To Combination Therapy Of Pazopanib And Paclitaxel In Platinum-resistant/refractory Ovarian Cancer | 2019 |
|
Dr Jingky Lozano-Kuehne
| Altered cytochrome 2E1 and 3A P450‐dependent drug metabolism in advanced ovarian cancer correlates to tumour‐associated inflammation | 2019 |
|
Dr Jingky Lozano-Kuehne
| Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in chronic kidney disease: results of the SHARP trial | 2016 |
|
Dr Jingky Lozano-Kuehne
| An assessment of chronotype and social jet lag among Filipinos | 2015 |
|
Dr Jingky Lozano-Kuehne
| What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? | 2015 |
|
Dr Jingky Lozano-Kuehne
| Genetic Variation I148M in Patatin-Like Phospholipase 3 Gene and Risk of Non-Alcoholic Fatty Liver Disease Among Filipinos | 2014 |
|
Dr Jingky Lozano-Kuehne
| Cancer Resources | 2013 |
|
Dr Jingky Lozano-Kuehne
| Disease Databases | 2013 |
|
Dr Jingky Lozano-Kuehne
| SNPedia | 2013 |
|
Dr Jingky Lozano-Kuehne
| Allelic and genotype frequencies of catechol-Omethyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines | 2012 |
|
Dr Jingky Lozano-Kuehne
| Association of glutathione S-transferase T1 and M1 genotypes with chronic liver diseases among Filipinos | 2012 |
|
Dr Jingky Lozano-Kuehne
| Shift work research in the Philippines: current state and future directions | 2012 |
|
Dr Jingky Lozano-Kuehne
| A generalized method for analyzing genetic main effects and epistasis among candidate genes using parent-offspring trios | 2010 |
|
Dr Jingky Lozano-Kuehne
| Foundations of Statistical Analysis for the Health Science | 2010 |
|
Dr Jingky Lozano-Kuehne
| Generalized Method in Candidate Gene Analysis for Nonnormally Distributed Quantitative Traits using Family Trios | 2010 |
|
Dr Jingky Lozano-Kuehne
| Generalized Quantitative Transmission Disequilibrium Test for Analyzing Genetic Main Effects and Epistasis | 2010 |
|
Dr Jingky Lozano-Kuehne
| The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells | 2010 |
|
Dr Jingky Lozano-Kuehne
| Tests for candidate gene interaction for longitudinal quantitative traits measured in a large cohort | 2009 |
|
Dr Jingky Lozano-Kuehne
| Issues in association mapping with high-density SNP data and diverse family structures | 2007 |
|
Dr Jingky Lozano-Kuehne
| The heat shock protein HSP70 promotes mouse NK cell activity against tumors which express inducible NKG2D ligands | 2007 |
|
Dr Jingky Lozano-Kuehne
| Chest radiograph aortic arch calcification is a surrogate marker of coronary artery disease | 2004 |
|
